Chinese Journal of Clinical Anatomy ›› 2023, Vol. 41 ›› Issue (1): 77-80.doi: 10.13418/j.issn.1001-165x.2023.1.14

Previous Articles     Next Articles

Triptolide prevents bone loss by inhibiting osteoclastogenesis 

Chen Junze1, Yu Hui2, Xiao Jin2*   

  1. 1. Baiyun Branch, Southern Hospital of Southern Medical University, Guangzhou 510420, China; 2. Guangdong Provincial People's Hospital, Guangzhou 510080, China 
  • Received:2021-10-22 Online:2023-01-25 Published:2023-02-08

Abstract: Objective    To investigate the antiosteoporotic effect and mechanism of triptolide. Methods    A rat model of senile osteoporosis was established. Forty 22-month-old male SD rats were randomly divided into a treatment group of triptolide (15 μg/kg per day intraperitoneally) and a control group of saline (15 μg/kg per day intraperitoneally) for 8 weeks treatment. Bone mineral density (BMD) and bone microstructure of the proximal tibial cancellous were analyzed by micro-CT. Western blot was used to detect the expression level of osteogenic-related proteins. The number of osteoclasts was measured by TRACP-5b staining, and the expression levels of bone resorption markers were also detected.    Results    Micro-CT results showed that BMD, bone volume/total volume ratio (Bv/Tv), bone trabecular thickness (Tb.Th), bone trabecular number (Tb.N), and bone trabecular spacing (Tb.Sp) in the rats treated with ryanodine were significantly higher than those in the control group (P<0.05). There was no significant difference in osteogenesis-related protein expression between the two groups, and TRACP staining result showed that triptolide reduced the number of osteoclasts in vivo (P<0.05), while blood bone resorption marker levels were also significantly lower (P<0.05).    Conclusions    Triptolide has a protective effect on age-related osteoporosis by inhibiting osteoclastogenesis. Which may be a feasible option for the treatment of senile osteoporosis.

Key words: Triptolide; ,  , Osteoporosis; ,  , Osteoblast; ,  , Osteoclast

CLC Number: